Direct Rx recalls DULOXETINE D/R
- Published
- 1 Jul 2026
- Units affected
- 263 Bottles
- Agency
- FDA
- Country
- United States
The hazard
CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit
Classification: Class II — this product may cause temporary or medically reversible health problems; the chance of serious harm is remote.
What to do
Do not stop a prescribed medicine without talking to your doctor or pharmacist first. Ask them about a replacement, and return the recalled product to the pharmacy.
- Check the lot number on the box or bottle.
- Talk to your pharmacist or doctor before stopping any prescribed medicine.
- Return the product to the pharmacy for safe disposal.
Product details
DULOXETINE D/R, a) 30 mg (NDC 61919-482-30), 30 Caps; b) 30 mg (NDC 61919-482-60), 60 Caps; CYMBALTA, Packaged and Distributed by Direct Rx.
- Brand / company
- Direct Rx
- Codes / lots
- Lot: a) 09JA2530, 31JA2507, expires: 04/30/2027; b) Lot: 09DE2412, 09JA2528, 29JA2511, expires: 04/30/2027.
- Distribution
- U.S. Nationwide
- Recall status
- Ongoing
Source: U.S. Food and Drug Administration, published 1 Jul 2026. CheckMyRecalls reproduces the official notice in summary; always confirm the details with the original notice.